Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Natera (DE:45E)
BERLIN:45E
Holding DE:45E?
Track your performance easily
45E Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€54.00 - €167.00
Previous Close€158
Volume0.00
Average Volume (3M)59.00
Market Cap
€20.01B
Enterprise Value€20.43B
Total Cash (Recent Filing)$29.50M
Total Debt (Recent Filing)$465.97M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Feb 26, 2025EPS Estimate
-€0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding132,020,816
10 Day Avg. Volume39
30 Day Avg. Volume59
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)23.76
Price to Sales (P/S)13.62
Price to Cash Flow (P/CF)100.80
P/FCF Ratio134.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.33
Enterprise Value/Gross Profit41.45
Enterprise Value/Ebitda-200.89
Forecast
1Y Price Target
€171.38Price Target Upside8.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Natera News
PremiumCompany Announcements
Natera Aligns Executive Chairman’s Pay with Performance
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceNatera unveils groundbreaking data at ESMO, which strengthens its case for Signatera MRD inclusion into key NCCN guidelines.
Financial PerformanceRevenue of $413M (+58% y/y) came in above MSe/cons. $337/343M driven by an increase in testing volume, ASP per test, and OOP collections.
Market PositionNTRA remains a growth story with its leading MRD franchise serving a $20B market and a strong base with leadership position in NIPT and Carrier screening.
Bears Say
Efficacy ConcernsAnalysts are less confident in overall survival benefit, which KOLs are looking for, given DFS benefit expected to be small.
Study DelayNTRA announced that the highly anticipated ALTAIR CRC study is getting pushed out by 4 months, which might raise questions if it will impact timelines from the guidelines committee at NCCN.
Trial Design IssuesConcerns exist around the trial design of ALTAIR, including LONSURF being introduced as 2nd or 3rd line therapy.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.88% Insiders
28.19% Mutual Funds
34.30% Other Institutional Investors
18.37% Public Companies and
Individual Investors
45E FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was €54.00 and its highest was €167.00 in the past 12 months.
What is Natera’s market cap?
Currently, no data Available
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is Feb 26, 2025 which is in 67 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Nov 12, 2024. The company reported -€0.248 earnings per share for the quarter, beating the consensus estimate of -€0.548 by €0.3.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -€0.47.
How many shares outstanding does Natera have?
Natera has 132,020,810 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -€0.248 in its last earnings report, beating expectations of -€0.548. Following the earnings report the stock price went up 24%.
Which hedge fund is a major shareholder of Natera?
Among the largest hedge funds holding Natera’s share is Farallon Capital Management, L.L.C.. It holds Natera’s shares valued at 579M.
---
Natera Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€171.38 (8.47% Upside)
€171.38 (8.47% Upside)
Blogger Sentiment
Bullish
DE:45E Sentiment 75%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $17.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
182.61%
12-Months-Change
Fundamentals
Return on Equity
-25.82%
Trailing 12-Months
Asset Growth
9.98%
Trailing 12-Months
Company Description
Natera
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
---
45E Company Deck
---
45E Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Natera's strong financial and operational performance, with record revenue growth, increased oncology test volumes, and significant clinical data achievements. While there were some challenges related to weather impacts and litigation expenses, the overall outlook remains positive with raised guidance and strong cash flow generation.Read More>---
45E Stock 12 Month Forecast
Average Price Target
€171.38
▲(8.47% Upside)
Technical Analysis
Best Analysts Covering 45E
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+50.97%
reiterated a buy rating 6 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +50.97% per trade.
---